Boston Scientific to acquire Axonics for $71.00 per share in cash

BOSTON SCIENTIFIC CORP

Each Axonics share will be converted into $71.00 in cash, without interest.
Termination fee of $75M payable by Axonics for superior proposal; $140M payable by Boston Scientific if antitrust fails after Axonics stockholder approval.
Transaction subject to Axonics stockholder approval, HSR waiting period, and other regulatory consents.
Axonics board unanimously recommends adoption of the merger agreement.
Customary no-shop clause with fiduciary out allows Axonics to consider superior proposals.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

BOSTON SCIENTIFIC CORP entered into Agreement and Plan of Merger with Axonics, Inc. valued at Merger consideration of $71.00 per share in cash (effective 2024-01-08).

Action: entry
Agreement: merger
Counterparty: Axonics, Inc.
Value: Merger consideration of $71.00 per share in cash
Effective: 2024-01-08

Exact text from the filing

On January 8, 2024, Boston Scientific Corporation, a Delaware corporation (the “ Company ”), entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) with Sadie Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (“ Merger Sub ”), and Axonics, Inc., a Delaware corporation (“ Axonics ”), providing for the merger of Merger Sub with and into Axonics (the “ Merger ”), with Axonics surviving the Merger as a wholly owned subsidiary of the Company.

View on SEC.gov

23 material agreements filed in the last 30 days. Browse all material agreements →

BOSTON SCIENTIFIC CORP filing history →

Source: SEC EDGAR

accession 0000885725-24-000007

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.